Machine signal
Active cluster sell — 4 distinct insiders, $5.2M, window ends Sep 15, 2026.
Figures computed from official regulatory filings — .
Analysttarget 99.5 USD (+36%) · consensus 4.9/5 · 10 buy · 0 hold · 0 sell
Ownershipinsiders 2.69% · institutions 99.92% · short 13.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Tarsus Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
11 buys260 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| YARNO WENDY L | Exercise | n/a (No price was disclosed in the filing) | SEC |
| LINK WILLIAM J PHD | Sell | $60K | SEC |
| LINK WILLIAM J PHD | Sell | $914.5K | SEC |
| LINK WILLIAM J PHD | Exercise | n/a (No price was disclosed in the filing) | SEC |
| PYOTT DAVID E Itrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| PYOTT DAVID E Itrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LINK WILLIAM J PHD | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LINK WILLIAM J PHD | Sell | $5.3K | SEC |
| YARNO WENDY L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lin Elizabeth Yeu | Sell | $143.1K | SEC |
| Azamian Bobak R. | Sell | $640.9K | SEC |
| Lin Elizabeth Yeu | Sell | $484.7K | Unusual size | SEC |
| Neervannan Seshadri | Sell | $387.9K | SEC |
| Lin Elizabeth Yeu | Sell | $135.2K | SEC |
| Lin Elizabeth Yeu | Sell | $457.9K | SEC |
| Azamian Bobak R. | Sell | $264.7K | SEC |
| Azamian Bobak R. | Sell | $800.6K | SEC |
| Lin Elizabeth Yeu | Sell | $127.2K | SEC |
| Lin Elizabeth Yeu | Sell | $339.8K | Unusual size | SEC |
| Lin Elizabeth Yeu | Sell | $431K | Unusual size | SEC |
| Morrison Scott W | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PYOTT DAVID E Itrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Goodrich Katherine | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Morrison Scott W | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Goodrich Katherine | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |